Lonza Acquires Rights to Nona Biosciences’ TfR1 Blood-Brain Barrier Technology, Bolstering CNS Therapeutic Delivery Capabilities

Lonza Press Release Switzerland

Overview

Lonza has acquired the rights to Nona Biosciences’ Transferrin Receptor 1 (TfR1) blood-brain barrier (BBB) technology, expanding its strategic collaboration with Nona. This acquisition aims to significantly enhance Lonza’s ability to deliver biologics to the brain, accelerating the development of central nervous system (CNS) disorder therapeutics. The TfR1 BBB technology holds promise in solving the long-standing challenge of effective drug delivery across the blood-brain barrier.

In Depth

Key Findings

Lonza has secured the rights to Nona Biosciences’ Transferrin Receptor 1 (TfR1) blood-brain barrier (BBB) technology, concurrently expanding its strategic alliance with Nona. This pivotal move is designed to significantly enhance Lonza’s capabilities in delivering biologics to the brain, thereby accelerating the development of innovative therapeutic agents for central nervous system (CNS) disorders.

Technical / Clinical Details

The blood-brain barrier (BBB) is a highly selective barrier that protects the brain from circulating blood, impeding the delivery of many promising therapeutics, especially large biological molecules, to the brain. The TfR1 BBB technology works by targeting Transferrin Receptor 1, facilitating the active transport of therapeutic molecules across the BBB and into brain tissue. This approach utilizes specific ligands or antibodies to leverage TfR1-mediated transcytosis, offering a safer and more efficient drug delivery mechanism compared to traditional invasive methods that bypass the BBB. Lonza plans to integrate this technology into its extensive biologics development and manufacturing portfolio, aiming to expand therapeutic options for CNS disorders such as Alzheimer’s, Parkinson’s, multiple sclerosis, and brain tumors.

Background & Context

Central nervous system (CNS) disorders represent an area with exceptionally high unmet medical needs, and effective drug delivery to the brain has been a formidable challenge for decades. This difficulty has been one of the primary bottlenecks in the development of CNS therapeutics. Advancements like TfR1 BBB technology are crucial for overcoming this hurdle, paving the way for new therapeutic modalities to reach patients with brain diseases. For a CDMO like Lonza to integrate this technology means providing biopharmaceutical developers with specialized expertise and manufacturing solutions to more rapidly advance their pipelines of BBB-penetrating drug candidates.

Strategic Significance & Outlook

Lonza’s acquisition of Nona Biosciences’ TfR1 BBB technology rights and the expanded partnership have the potential to significantly reshape the landscape of CNS therapeutic development. By integrating this technology, Lonza establishes a unique position to support the development of next-generation biologics that can act in the central nervous system. This is expected to bring new hope to patients suffering from CNS disorders who have limited effective treatment options and could lead to a surge in innovative CNS therapeutics reaching the market in the future. Lonza’s strategic investment is poised not only to accelerate its own growth but also to contribute substantially to innovation across the broader biopharmaceutical industry.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime